Lindsey Shapiro, PhD,  science writer—

The Mayo Clinic will use a digital clinical trial platform developed by Triall in an upcoming pulmonary arterial hypertension (PAH) study. The platform will support all core activities related to the study, including data capture, document management, monitoring, and electronic consent forms to safeguard the integrity of…

Measuring blood levels of a certain type of DNA released by damaged cells — called cell-free DNA — may be a way to monitor disease severity in people with pulmonary arterial hypertension (PAH), a study found. The study’s researchers from the National Institutes of Health (NIH) say the test…

Blood levels of IL-6 and PTX3 — two inflammatory proteins — could serve as prognostic biomarkers in people with pulmonary hypertension (PH) associated with left-sided heart disease, a study suggests. Higher levels of both were linked to a greater risk of dying and higher levels of NT-proBNP, a known…

Nearly a third (29.7%) of COVID-19 patients showed signs of pulmonary hypertension (PH) on an echocardiogram — a scan of heart movement — according to a study in the Netherlands. While mortality rates were significantly higher among those with suspected PH than those without it, follow-up tests suggested that…

People with pulmonary arterial hypertension (PAH) have a distinct immune profile compared with healthy individuals, according to a new study that also found different activity levels in PAH patients of genes involved in pulmonary vascular remodeling, oxygen transport, and blood cell development. In fact, more than 1,200 genes were…

The use of the hormone vasopressin successfully stabilized symptoms associated with pulmonary hypertension (PH) in newborns, and avoided the need for more invasive treatment approaches in some infants, according to data from 10 cases. “Although our findings are exploratory and further research is needed to establish safety and efficacy,…

The leading causes of death among people with pulmonary hypertension (PH) differ by PH type, a Japanese study has found. When categorized using the World Health Organization (WHO) PH classification, those in group 1 died mostly from PH itself, those in group 3 died more often from…

High scores on a measure known as H2FPEF — which reflect an increased probability of dysfunction of the left ventricle (LV) of the heart — were associated with signs of LV impairment and a worse prognosis in patients with idiopathic pulmonary arterial hypertension (IPAH), a study found. Patients with…

Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). Developed through a collaboration of scientists at Anumana, Janssen Research and Development, and the Mayo Clinic, the artificial intelligence (AI)-powered algorithm is designed…

To celebrate World Pulmonary Hypertension Day on May 5, Ferrer and the European Pulmonary Hypertension Association (PHA Europe) have launched the PHantasticals campaign to raise public awareness about rare and chronic lung diseases like pulmonary hypertension (PH). The campaign features a collection of mermaid characters called the…

Chiesi Farmaceutici has acquired the worldwide rights to a number of investigational antibodies that may be able to treat pulmonary arterial hypertension (PAH) from the developer, Allinaire Therapeutics. All of the antibodies act against the endothelial monocyte-activating polypeptide (EMAP II), a pro-inflammatory molecule that is thought to…

Longer-term use of Ventavis (iloprost) as an add-on therapy significantly improved blood flow and lowered blood pressure in people with pulmonary arterial hypertension (PAH), a small study in Japan reported. Findings support this inhaled therapy’s established benefits as a pulmonary vasodilator — a medicine that  widens, or dilate,…